Gilead Sciences’ Kite Reports Ongoing Response in 39% of Lymphoma Patients at Two Years in Study of Yescarta

Gilead Sciences (GILD) rose more than 2% in Monday’s pre-market session after the company said that its subsidiary, Kite, reported efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta in patients with refractory large B-cell lymphoma, saying that two years following a single infusion of Yescarta, 39% of patients were in an ongoing response. At two years, the […]